2000•PubMedRequires access

[The prognostic factors for survival in advanced forms of non-small-cell lung cancer].

Lucian Miron, Catalin Toma, L Ciornea

Open publisher page 1 citations

Abstract

UNLABELLED: This study attempted to determinate the prognostic value for survival of various clinical, biological and therapeutical prognostic factors in patients with non-resectable non-small cell lung cancer (NSCLC). METHOD: We performed a retrospective study on 236 patients with histologically proved unresectable NSCLC. We collected 36 variable and analysed them by univariate and multivariate methods in order to establish their influence on survival. RESULTS: The global estimated median survival time was 10 month. In univariate analysis were significantly related to survival: age (> 60 years), weight loss (> 5%), local extend of of disease, Karnofsky performance index (< 70%), stage of disease (stage IIIA vs. IIIB, IV), hemoglobinemia (< 10 g%), calcemia, platelet count, radiotherapy total dose (< 50 Gy), Cisplatin chemotherapy. In a Cox regression model, the explanatory variables were: age > 60 years, Karnofsy performance index 70%, stage IIIB and IV, thoracic total radiotherapy dose < 50 Gy. These results led to a classification of the patients into three subgroups (prognostic index). CONCLUSION: We confirm by our analysis the role of independent factors for survival and we obtained three prognostic groups, the best one needs a radio-chemotherapy association.

About this research paper

What this paper is about

UNLABELLED: This study attempted to determinate the prognostic value for survival of various clinical, biological and therapeutical prognostic factors in patients with non-resectable non-small cell lung cancer (NSCLC). METHOD: We performed a retrospective study on 236 patients with histologically proved unresectable NSCLC. We collected 36 variable and analysed them by univariate and multivariate methods in order to establish their influence on survival. RESULTS: The global estimated median survival time was 10 month. In univariate analysis were significantly related to survival: age (> 60 years), weight loss (> 5%), local extend of of disease, Karnofsky performance index (< 70%), stage of disease (stage IIIA vs. IIIB, IV), hemoglobinemia (< 10 g%), calcemia, platelet count, radiotherapy total dose (< 50 Gy), Cisplatin chemotherapy. In a Cox regression model, the explanatory variables were: age > 60 years, Karnofsy performance index 70%, stage IIIB and IV, thoracic total radiotherapy dose < 50 Gy. These results led to a classification of the patients into three subgroups (prognostic index). CONCLUSION: We confirm by our analysis the role of independent factors for survival and we obtained three prognostic groups, the best one needs a radio-chemotherapy association.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

UNLABELLED: This study attempted to determinate the prognostic value for survival of various clinical, biological and therapeutical prognostic factors in patients with non-resectable non-small cell lung cancer (NSCLC). METHOD: We performed a retrospective study on 236 patients with histologically proved unresectable NSCLC. We collected 36 variable and analysed them by univariate and multivariate methods in order to establish their influence on survival. RESULTS: The global estimated median survival time was 10 month. In univariate analysis were significantly related to survival: age (> 60 years), weight loss (> 5%), local extend of of disease, Karnofsky performance index (< 70%), stage of disease (stage IIIA vs. IIIB, IV), hemoglobinemia (< 10 g%), calcemia, platelet count, radiotherapy total dose (< 50 Gy), Cisplatin chemotherapy. In a Cox regression model, the explanatory variables were: age > 60 years, Karnofsy performance index 70%, stage IIIB and IV, thoracic total radiotherapy dose < 50 Gy. These results led to a classification of the patients into three subgroups (prognostic index). CONCLUSION: We confirm by our analysis the role of independent factors for survival and we obtained three prognostic groups, the best one needs a radio-chemotherapy association.

Key concepts: Medicine, Internal medicine, Lung cancer, Proportional hazards model, Radiation therapy, Univariate analysis, Multivariate analysis, Performance status

Related papers

Back to paper searchBrowse research topicsOriginal source
[The prognostic factors for survival in advanced forms of non-small-cell lung cancer]. — Research Paper | ScholarLens